• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Appendix E: Development of Costs for the Process for the Review of Abbreviated Applications for Generic New Animal Drugs - FY 2011 AGDUFA Financial Report

Back to Table of Contents: FY 2011 AGDUFA Financial Report

 

General Methodology

 

The costs associated with the process for the review of abbreviated applications for generic new animal drugs are based on obligations recorded within FDA’s CVM, ORA, and FDA Headquarters (HQ), formerly known as the Office of the Commissioner. These organizations correspond to the cost categories presented as follows:

 

 Cost Category

FDA Organization

 Costs for the Review of Abbreviated ANADAs, Supplemental Animal Generic Applications and Investigational Submissions for Generic New Animal Drugs  CVM
 Costs for Field Pre-approval Inspection and Investigation ORA
 Costs for Agency General and Administrative Activities HQ
 

The costs were derived mostly from time reporting systems in CVM and ORA, and were calculated for HQ as described in more detail in this Appendix.  Using the definitions of costs and activities included in the process for the review of generic new animal drug applications in AGDUFA, as explained in the discussion in Appendix D, the cost categories within each organization listed above were identified as parts of the generic new animal drug review process.

 

 

Table 11

Office of Regulatory Affairs

Costs of the Review Process for Abbreviated Applications for

Generic New Animal Drugs

as of September 30, 2011

 

 

 COST COMPONENT FY 2010 FY 2011
 Staff Years Utilized 2 1
 ORA Average Salary and Benefits  $108,065 $110,499
 Total Salary and Benefits $216,130 $110,499
 Operating and Other Costs1 $187,015 $102,437
 GRAND TOTAL (salary/benefits and operating/other costs) $403,145 $212,936

 

 1Other costs are central, GSA rent, rent related, and Shared Services costs that are applicable to the process for the review of generic animal drug applications.

 

ORA costs for the process for the review of generic animal drug applications described above include total process costs, including costs paid from appropriations and costs paid from fee revenues. The decrease in ORA total costs of the review process for abbreviated applications for generic new animal drugs from FY 2010 can be attributed to fewer inspections requested by the Center for Veterinary Medicine for ORA to conduct under AGDUFA in FY 2011.

 

 

Agency General and Administrative Costs

 

The Agency general and administrative costs include all costs incurred in FDA’s HQ that are attributable to the Office of the Commissioner and all other FDA headquarters components that are not Centers or the Office of Regulatory Affairs.  For the purpose of these calculations, HQ is considered to be comprised of the following offices:

 

·         Immediate Office of the Commissioner

·         Office of the Counselor to the Commissioner

·         Office of Legislation

·         Office of Policy and Planning

·         Office of External Affairs

·         Office of the Executive Secretariat

·         Office of the Chief Counsel

·         Office of Minority Health

·         Office of Women’s Health

·         Office of the Chief Scientist (excluding the National Center for Toxicological Research)

·         Office of Operations

·         Office of Foods (excluding the Center for Food Safety and Applied Nutrition and the Center for Veterinary Medicine)

·         Office of Medical Products and Tobacco (excluding the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Tobacco Products)

·         Office of Global Regulatory Operations and Policy (excluding the Office of Regulatory Affairs)

 

In summary, HQ costs include all of FDA except for the six product-oriented Centers, the Office of Regulatory Affairs, and the National Center for Toxicological Research.

 

The HQ costs applicable to the process for the review of generic new animal drugs were calculated using a method prescribed by the Division of Cost Determination Management, Office of Finance, Office of the Secretary, Department of Health and Human Services.  The method uses the percentage derived by dividing total HQ costs by the total FDA salary expenses (excluding benefits) after subtracting the salary expense (excluding benefits) from HQ.  That percentage is then multiplied by the sum of salaries (excluding benefits) applicable to the process for the review of abbreviated applications for generic new animal drugs in CVM and ORA to derive the applicable Agency general and administrative costs.

 

Using this methodology, FDA dedicated $817,505 in general and administrative costs to the generic animal drug review process in FY 2011.  The costs are total costs obligated from appropriations and user fees.  FDA strives to maintain a low overhead cost for the review process of the abbreviated applications for generic new animal drugs.  General and administrative costs are approximately 7.1 percent of FY 2011 generic new animal drug review process costs.

 

Center Costs

 

Costs of the generic animal drug application review program are tracked for each organizational component in CVM, usually at the division level.  Most CVM components involved in the generic new animal drug review process perform a mixture of activities – some within the definition of the process for the review of generic new animal drug applications, and some not.  CVM groups its organizational components into three categories:

 

·         direct process activities, such as submission specific work;

·         indirect process and support activities, such as standard operating procedures and application review support; and

·         Center-wide costs. 

 

 

CVM’s Activity Time Reporting (ATR) System supports the allocations for all three areas.

 

CVM’s ATR

 

Using the Activity Dictionary in conjunction with the definition of the process for the review of abbreviated applications for generic new animal drugs in AGDUFA, CVM was able to attribute activity time reported by its employees to direct and indirect process and support activities as distinguished from non-process activities.  These activity definitions are consistent with the allowable costs for the process of the review of abbreviated applications for generic new animal drugs as detailed in Appendix D.

 

Agency-Wide Expenses

 

A number of Center-wide and Agency-wide expenses are paid from the central accounts of the Center or of FDA rather than from funds allocated to a specific Center or division or office within the Center.  These costs include rent for facilities that house CVM staff, telecommunications and utility costs, some computer equipment and support costs, and costs of the Office of Shared Services, which supports all FDA programs and activities.  For these Center- and Agency-wide costs, a percentage of them are chargeable to the process for the review of animal drug applications.  That percentage is either a specific amount that is supported by independent documentation or is the amount of time reported for allowable activities (direct and indirect) in the Center, as a percentage of total time reported for all Center direct and indirect activities.

 

In support of the previous Administrations Management Agenda and Goal of “One-HHS”, FDA was requested to consolidate its administrative functions (including facilities, procurement, finance, equal employment opportunities, and information technology services) to carry out more efficient realignment of the resources which would provide high quality administrative services from a single organization.  FDA created an Office of Shared Services in FY 2004.  It combined the support responsibilities and resources previously located both in the Centers and in HQ, and ensured effective and efficient services in a competitive market environment.  In this report resources expended by the Office of Shared Services in supporting the generic new animal drug review process are reported as if they were incurred in CVM, ORA, or HQ.

 

Field Inspection and Investigation Costs

 

ORA incurs all field inspection, investigation, and laboratory analyses costs.  ORA costs are incurred in both district offices (the “field”) and headquarters offices, which are tracked in FACTS.  FACTS is a time and activity tracking system that captures time spent in a variety of categories, including pre-approval inspections of manufacturing facilities, investigations of clinical studies, and analytical testing of samples, which are all part of the review process for generic animal drug applications.

 

Total direct hours reported in FACTS are used to calculate the total number of staff-years required by ORA to perform these activities.  In addition to the direct time, an allocation of support time is also included to represent the work done by the ORA administrative and management personnel.  The agency, then, multiplies the total number of staff-years used in the process for the review of generic animal drug applications by the average salary cost in ORA to arrive at ORA salary costs for work that is a part of the process for the review of abbreviated applications for generic new animal drugs as defined in AGDUFA.  The final step is to allocate ORA obligations for operations and rent to the generic animal drug review process based upon the ratio of user fee related staff-years to total ORA staff-years. 

 

Table 11 summarizes the calculation of ORA costs for the review of abbreviated applications for generic new animal drugs for FY 2010 and FY 2011.